Andreas Strüngmann
Andreas Strüngmann (born 1950) is a German businessman and founded generic drug maker Hexal AG ($1.6 billion sales during 2004) in 1986. It became Germany's second-largest generic drug producer.[1] In February 2005, he and his brother Thomas sold Hexal and their 67.7% of U.S. Eon Labs to Novartis for $7.5 billion,[2] making its subsidiary Sandoz the largest generic-drug company in the world.
Andreas Strüngmann | |
|---|---|
| Born | 1950 (age 71–72) |
| Education | University of Buffalo |
| Occupation | Entrepreneur |
| Known for | Co-founder of Hexal |
He currently has residences in Tegernsee and South Africa and is married with two children. At age 56, he accepted an executive position at Sandoz, a generics division of Novartis.
See also
References
- Timmons, Heather & Wright, Tom. "Novartis to Buy Two Makers of Generics". The New York Times, 22 February 2005. Retrieved on 27 May 2013.
- Forbes. "Andreas Strungmann - Forbes". March 2013. Retrieved on 27 May 2013.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.